Debiopharm, a privately owned Swiss biopharmaceutical company, and Alkyon Therapeutics, a biotechnology company pioneering precision-targeted therapies, signed a co-research agreement.

Together, the companies will evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm’s proprietary AbYlink conjugation technology for Alkyon’s modular antibody platform directed against undisclosed tumor-associated antigens.

The goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. 

AbYLink technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing.

“This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,” said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. “By applying AbYlink to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.”